Affinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease

Documenti analoghi

• Editorial: Silent But Detectable—High‐Throughput Proteomics to Identify Clinically Significant Liver Disease
  di: Emily Stephenson, et al.
  Pubblicazione: (2026)
• The Prevalence and Risk Factors for at‐Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care
  di: Leon A. Adams, et al.
  Pubblicazione: (2026)
• Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
  di: Jee‐Fu Huang, et al.
  Pubblicazione: (2026)
• Regarding: Alpha‐1 antitrypsin deficiency associated with increased risks of skin cancer, leukemia, and hepatic cancer: A nationwide cohort study
  di: Malin Fromme, et al.
  Pubblicazione: (2024)
• Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
  di: Pojsakorn Danpanichkul, et al.
  Pubblicazione: (2025)